NCT01926977View on ClinicalTrials.gov

Evaluation of Pain and Inflammation After Injection of Lucentis vs Eylea for Treatment of Wet Macular Degeneration

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions
Neovascular Age-Related Macular Degeneration
Interventions
DRUG

Ranibizumab 0.5mg

Patient will receive intravitreal injection of Ranibizumab 0.5mg.

DRUG

Aflibercept 2.0mg

Patients will receive intravitreal injection of Aflibercept 2.0mg.

Trial Locations (1)

89502

Sierra Eye Associates, Reno

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Arshad Khanani

OTHER

NCT01926977 - Evaluation of Pain and Inflammation After Injection of Lucentis vs Eylea for Treatment of Wet Macular Degeneration | Biotech Hunter | Biotech Hunter